Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension

Exclusion Criteria

• •1. Clinically significant ocular disease
• •2. Pseudoexfoliation or pigment dispersion component glaucoma, history of angle closure or narrow angles
• •3. Unmedicated intraocular pressure ≥30mmHg
• •4. Use of more than 2 ocular hypotensive medications within 30 days of screening
• •5. Known hypersensitivity to any component of the formulation
• •6. Previous glaucoma surgery or refractive surgery
• •7. Ocular trauma within 6 months prior to screening
• •8. Any ocular surgery or non-refractive laser treatment within 3 months prior to screening
• •9. Recent or current ocular infection or inflammation in either eye
• •10. Used ocular medication in either eye of any kind within 30 days of screening
• •11. Mean central corneal thickness \>620µm at screening
• •12. Any abnormality preventing reliable applanation tonometry of either eye
• •13. Clinically significant abnormalities in lab tests at screening
• •14. Known hypersensitivity or contraindication to beta-adrenoceptor antagonists
• •15. Clinically significant systemic disease
• •16. Participation in any investigational study within 60 days prior to screening
• •17. Used any systemic medication that could have a substantial effect in intraocular pressure within 30 days prior to screening
• •18. Women who are pregnant, nursing, planning a pregnancy or not using a medically acceptable form of birth control